Ernexa Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)2.14 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $2.96Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $3.5M Enterprise Value −$5.3M Shares Outstanding 1.2M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ernexa Therapeutics is at a critical inflection point as it transitions from a preclinical platform to a clinical-stage biotechnology company. The company's core technology focuses on engineering induced pluripotent stem cells (iPSCs) into synthetic, allogeneic induced mesenchymal stem cells (iMSCs) that home to tumors and deliver localized therapeutic payloads. Preclinical data for its lead candidate, ERNA-101, in combination with PD-1 blockade, demonstrated 100% long-term survival and complete tumor clearance in ovarian cancer models. With a successful pre-IND meeting completed, an IND submission planned for Q3 2026, and a Phase 1 trial targeted for Q4 2026, Ernexa offers a highly asymmetric risk/reward profile supported by a consensus analyst price target of $30.00. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$30.00 Mean target$30.00 High · most bullish analyst$30.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.00 The FDA issues a clinical hold or requests additional preclinical/manufacturing data, delaying the IND clearance into 2027. Cash burn accelerates, forcing highly dilutive equity raises at depressed valuations under the ATM program. Preclinical efficacy fails to translate to human subjects, or safety concerns emerge regarding the engineered iMSC platform. Base CaseCentral scenario $15.00 Ernexa submits its IND in Q3 2026 and initiates the Phase 1 trial in Q4 2026 or early 2027. The company utilizes its ATM program to manage cash burn, resulting in moderate dilution. Preclinical validation translates to acceptable safety and early signs of efficacy in the Phase 1 cohort, keeping the clinical-stage transition on track. Bull CaseUpside scenario $30.00 ERNA-101 successfully receives FDA IND clearance in Q4 2026 and initiates its Phase 1 trial on schedule. Early clinical data validates the preclinical promise of 100% tumor clearance in platinum-resistant ovarian cancer, transforming immunologically 'cold' tumors into 'hot' ones. The company secures a high-value co-development partnership with a major pharmaceutical firm, providing non-dilutive capital and validating the off-the-shelf iMSC platform. The stock moves rapidly toward the consensus analyst target. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |